Skip to main content
Fig. 3 | International Journal of Arrhythmia

Fig. 3

From: Differences in anticoagulation strategy and outcome in atrial fibrillation patients with chronic kidney disease: a CODE-AF registry study

Fig. 3

Dosage of non-vitamin K oral anticoagulants (NOACs) in CKD patients. a Overall, b dabigatran, c rivaroxaban, and d apixaban. In the overall NOACs, the underdose rate was lower in CKD patients than in normal patients. CKD patients had a lower underdose rate and a higher optimal dose rate of dabigatran and rivaroxaban. However, CKD patients had a higher underdose rate and a lower optimal dose rate of apixaban. CKD, chronic kidney disease

Back to article page

International Journal of Arrhythmia

ISSN: 2466-1171

Contact us